Trial Profile
Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation: A Rotation Study of Different Albuminuria Lowering Drug Classes to Study Individual Drug Response in Diabetes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Linagliptin (Primary) ; Sulodexide (Primary) ; Telmisartan (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Therapeutic Use
- Acronyms ROTATE-2
- 25 Feb 2021 This trial is completed (Global End Date: 12 Jan 2021), according to European Clinical Trials Database record.
- 12 Sep 2018 Status changed from recruiting to withdrawn prior to enrolment as the study was registered and published incorrectly.
- 05 Oct 2017 New trial record